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The insecticide dichlorodiphenyltrichloro-
ethane (DDT) was first synthesized in 1874
and reached worldwide use during the early
1960s to control malaria and some agricul-
tural pests. In 1972 the use of DDT was
banned in the United States, and by the
beginning of the 1980s this chemical was
prohibited in most developed countries.
However in India, Indonesia, and Italy, DDT
was still produced until 1990, and in Mexico
DDT was in use until 1997 to control
malaria (Turusov et al. 2002). The long per-
sistence and environmental spreading exhib-
ited by DDT and its metabolites, along with
their estrogenic potential, are the main con-
cerns regarding its potential role in the etiol-
ogy of estrogen-related malignant tumors
(Snedeker 2001).
In 1993, Wolff et al. (1993) ﬁrst reported
on the presumed positive association between
p,p´-dichlorodiphenyldichloroethane
(p,p´-DDE)—the main metabolite of DDT—
and breast cancer, and subsequently the assess-
ment of the body burden of DDT metabolites
in relation to breast cancer risk received a lot
of attention. During the last decade, results
from several epidemiologic studies were pub-
lished but most were unable to replicate the
positive association between p,p´-DDE and
breast cancer risk. Among other explanations
for such negative results, some suggested—
but never proved—that single studies lacked
an adequate gradient of exposure to p,p´-DDE
among breast cancer cases and controls, and
this ﬂaw obscured the differences (Talbott et
al. 1998). As demonstrated below, the gradient
exposure in 22 published studies ranged from
84.37 to 12928.08 ng/g (Aronson et al. 2000;
Dello Iacovo et al. 1999; Demers et al. 2000;
Dorgan et al. 1999; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000b; Hunter et al. 1997;
Krieger et al. 1994; Laden et al. 2001b; López-
Carrillo et al. 1997; Mendonca et al. 1999;
Millikan et al. 2000; Moysich et al. 1998;
Romieu et al. 2000; Stellman et al. 2000; van´t
Veer et al. 1997; Wolff et al. 1993, 2000a,
2000b; Zheng et al. 1999, 2000), in sharp
contrast to the narrower gradients achieved by
most single studies.
Serum and adipose tissue were the human
biologic matrices used to estimate p,p´-DDE
body burden and its potential relationship
with breast cancer risk. Circulating lipids
influence blood levels of DDT metabolites
(Phillips et al. 1989), yet approaches to this
condition varied greatly in the published sci-
entiﬁc literature. Some studies reported p,p´-
DDE serum levels in lipid bases (Demers et
al. 2000; Dorgan et al. 1999; Helzlsouer et al.
1999; Hoyer et al. 1998, 2000a, 2000b;
Laden et al. 2001; López-Carrillo et al. 1997;
Millikan et al. 2000; Romieu et al. 2000;
Ward et al. 2000; Wolff et al. 2000a, 2000b;
Zheng et al. 2000), whereas others performed
an indirect adjustment by ﬁtting a cholesterol
term in linear regression models (Dello
Iacovo et al. 1999; Hunter et al. 1997;
Moysich et al. 1998) and the rest only 
provided wet-based measurements (Krieger et
al. 1994; Mendonca et al. 1999; Olaya-
Contreras et al. 1998; Schecter et al. 1997;
Wolff et al. 1993). This heterogeneity among
biologic matrices and reported units of cumu-
lative p,p´-DDE levels limited the ability to
evaluate the gradient of p,p´-DDE body bur-
den levels across the epidemiologic studies
published so far.
In this article we aim to a) estimate the
strength of the association between p,p´-DDE
and breast cancer on the basis of published
epidemiologic evidence; b) identify the gradi-
ent of exposure that was captured in the same
epidemiologic studies; and c) discuss the con-
sistency of published results in the context of
their main methodologic features.
Materials and Methods
We searched for the epidemiologic evidence
on p,p´-DDE and breast cancer risk in both
the MEDLINE and PubMed databases
(www.ncbi.nlm.nih.gov). A total of 35 ana-
lytic studies (Aronson et al. 2000; Bagga et al.
2000; Dello Iacovo et al. 1999; Demers et al.
2000; Dewailly et al. 1994; Dorgan et al.
1999; Duell et al. 2000; Falck et al. 1992;
Güttes et al. 1998; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000a, 2000b; Hunter et
al. 1997; Krieger et al. 1994; Laden et al.
2001a; Liljegren et al. 1998; López-Carrillo et
al. 1997; Mendonca et al. 1999; Millikan et
al. 2000; Moysich et al. 1998; Olaya-
Contreras et al, 1998; Romieu et al. 2000;
Schecter et al. 1997; Stellman et al. 2000;
Unger et al. 1982, 1984; van´t Veer et al.
1997; Ward et al. 2000; Wassermann et al.
1976; Wolff et al. 1993, 2000a, 2000b;
Zheng et al. 1999, 2000) that were published
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The relationship of dichlorodiphenyltrichloroethane (DDT) exposure and breast cancer risk has
received increasing attention since the beginning of the 1990s. Contradicting published results
regarding the relationship between body burden levels of p,p´-dichlorodiphenyldichloroethane (p,p´-
DDE)—the main DDT metabolite—and breast cancer, we argue that such differences stem from
methodologic differences among those studies. We performed a meta-analysis of 22 articles using
DerSimonian and Laird’s method for random effects models. The Q-statistic was used to identify
heterogeneity in the outcome variable across studies. The gradient of p,p´-DDE exposure in epi-
demiologic studies was homogenized to serum lipid bases (nanograms per gram). The potential for
publication bias was examined by means of the Begg’s test. We discuss methodologic features of the
studies in an attempt to reconcile the ﬁndings. The summary odds ratio (OR) for selected studies
was 0.97 (95% conﬁdence interval, 0.87–1.09) and the gradient of exposure ranged from 84.37 to
12,948 ng/g. No overall heterogeneity in the OR was observed (χ2 = 27.93; df = 23; p = 0.218).
Neither the study design nor the lack of breast-feeding control or the type of biologic specimen used
to measure p,p´-DDE levels were the causes of heterogeneity throughout the studies. Evidence for
publication bias was not found (p = 0.253). Overall, these results should be regarded as a strong evi-
dence to discard the putative relationship between p,p´-DDE and breast cancer risk. Nevertheless,
the exposure to DDT during critical periods of human development—from conception to adoles-
cence—and individual variations in metabolizing enzymes of DDT or its derivatives are still impor-
tant areas to be researched in regard to breast cancer development in adulthood. Key words: breast
cancer, DDT, epidemiology, evidence, meta-analysis. Environ Health Perspect 112:207–214 (2004).
doi:10.1289/ehp.6492 available via http://dx.doi.org/ [Online 22 October 2003]in English up to February 2001 were found
using the following MeSH headings, key, and
text words: breast cancer, organochlorines,
pesticides. The articles identified were then
reviewed to determine whether they met the
following inclusion criteria for statistical
analyses: to be epidemiologic cohort or
case–control studies; to have enrolled at least
50 cases; to have reported measures of associa-
tion and conﬁdence intervals (CIs) for breast
cancer risk; to have measured p,p´-DDE levels
in biologic samples (serum or adipose tissue);
and to have been published in journals listed
by the Journal Citation Reports—Science
Edition (JCR) (1999).
Under the former considerations, six arti-
cles were discarded because no measures of
association were reported (Dewailly et al.
1994; Falck et al. 1992; Güttes et al. 1998;
Unger et al. 1984, 1982; Wassermann et al.
1976), one more was eliminated because it
lacked CIs (Ward et al. 2000), another article
was excluded because the researchers evaluated
survival instead of breast cancer risk (Hoyer
et al. 2000a), another one did not measure
p,p´-DDE levels in biologic samples (Duell
et al. 2000), one was not published in a JCR
journal (Olaya-Contreras et al. 1998), two
reported on < 50 breast cancer cases (Liljegren
et al. 1998; Schecter et al. 1997) and one
study used a cross-sectional design (Bagga
et al. 2000). These 13 epidemiologic studies
were discarded in this step and 22 were kept
for further analyses (Aronson et al. 2000;
Dello Iacovo et al. 1999; Demers et al. 2000;
Dorgan et al. 1999; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000b; Hunter et al. 1997;
Krieger et al. 1994; Laden et al. 2001b; López-
Carrillo et al. 1997; Mendonca et al. 1999;
Millikan et al. 2000; Moysich et al. 1998;
Romieu et al. 2000; Stellman et al. 2000;
van´t Veer et al. 1997; Wolff et al. 1993,
2000a, 2000b; Zheng et al. 1999, 2000).
From each eligible report and using a pre-
deﬁned review form, two independent review-
ers extracted the following methodologic
information: name of the author, year and
place of publication, epidemiologic design,
type of controls and biologic specimens, con-
founding variables considered in the analysis,
and the measure of association estimated for
the highest versus lowest category of exposure
along with the corresponding CI.
After their extraction, we entered relevant
data into evidence tables. We then performed
a meta-analysis using the method of the
inverse of variance for fixed-effects models
and the DerSimonian and Laird method for
random-effects models. (DerSimonian and
Laird 1986). Separate odds ratios (ORs) were
used in the meta-analysis for one article that
reported estimates from population-based and
hospital controls (Demers et al. 2000), and
the same was done with estimates from one
study in which serum samples were taken and
analyzed for two different periods of time
(Helzlsouer et al. 1999). The results are dis-
played as summary ORs and 95% CIs for the
effect of p,p´-DDE on breast cancer, corre-
sponding to the contrast of the highest versus
the lowest level of p,p´-DDE exposure.
We plotted the outcomes for included
studies for visual examination and performed
meta-analysis regression using the Q-statistic
to identify heterogeneity in the outcome vari-
able across studies (Berkey et al. 1995;
DerSimonian and Laird 1986). Potential
sources of heterogeneity were evaluated,
including the study design, control for breast-
feeding and the kind of biologic specimen in
which the DDT metabolites were measured.
We assessed the potential for publication bias
using a funnel plot in conjunction with the
Begg’s test, which is based on the fact that
smaller studies tend to have larger effect size
estimates and the publication bias induces a
correlation between the effect estimates and
their variances (Begg 1985, 1994).
To estimate the trend of p,p´-DDE body
burden evaluated by the epidemiologic stud-
ies analyzed, we determined the crude mean
p,p´-DDE levels among cases and controls
reported by each study and homogenized
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Table 1. Prospective epidemiologic studies (nested case–control) on p,p´-DDE and breast cancer risk.
Controlled variablesa
Cases/controls  Biologic specimen Reproductive History of Other p,p´-DDE
Reference, location (n) Controls (year of collection) Age variables breast cancer variables ORs (95% CI)
Laden et al. 2001b 381/381 Free of cancer Serum X X X Xb High vs. low quintile
11 large states, USA (1989–1990) 0.82 (0.49–1.37)
Wolff et al. 2000b 110/213 Free of disease Serum X X X Xc High vs. low quartile
New York City, USA (1985–1991) 1.30 (0.51–3.35)
Hoyer et al. 2000b 240/477 Free of disease Serum X X — Xd High vs. low quartile
Copenhagen, Denmark (1976–1983) Except breast- 1.4 (0.7–2.8)
feeding
Dorgan et al. 1999 105/207 Free of cancer  Serum X — — Xe High vs. low quartile
Columbia, Missouri, USA except skin cancer (1977–1987) 0.8 (0.4–1.5)
Helzlsouer et al. 1999 235/235 Free of cancer Serum X X X Xf High vs. low quintile
Washington Co., Maryland, USA except skin cancer (1974) 0.73 (0.40–1.32)
105/105 Free of cancer Serum X X X Xf High vs. low tertile
except skin cancer (1989) 0.58 (0.29–1.17)
Hoyer et al. 1998 237/469 Free of breast cancer Serum X X — Xg High vs. low quartile
Copenhagen, Denmark (1976) Except breast- 0.88 (0.56–1.37)
feeding
Hunter et al. 1997 236/236 Free of cancer Serum X X X Xh High vs. low quintile
Boston, MA, USA (1989–1990) 0.72 (0.37–1.40)
Krieger et al. 1994 150/150 Free of cancer Serum X X — Xi High vs. low tertile
California, USA (1964–1971) Except breast- 1.33 (0.68–2.62)
feeding
Wolff et al. 1993 58/171 Free of cancer Serum X X X Xj High vs. low quintile
New York City, USA (1985–1991) 3.68 (1.01–13.5)
p-value for trend = 0.04
Abbreviations: BMI, body mass index; ln, natural logarithm. 
aIn design or analysis. bDate in which blood sample was returned, time of day that blood sample was obtained, fasting status at blood sampling and for postmenopausal homone use,
BMI at blood collection, history of benign breast disease. cNumber and dates of blood donations, day of menstrual cycle for premenopausal women, ln height, ln (BMI) –menopausal
status at blood donation interaction. dVital statistics at time of diagnosis and weight. eYear of blood draw and history of benign disease at the time of diagnosis. fDate of blood donation
and day of menstrual cycle, race, BMI at age 20 or current. gDate of examination and vital status at the time of diagnosis, weight, height, alcohol consumption, smoking, physical activity,
income, marital status, and education. hSerum lipids, month in which the blood sample was returned, time of day that the blood sample was obtained, fasting status at blood sampling,
postmenopausal hormone use, history of benign breast disease, BMI. iDate of examination, length of follow-up after examination, race, date of joining the Kaiser Permanente Medical
Care Program, year of multiphasic examination and BMI. jNumber and date of blood donation, if premenopausal women: day of menstrual cycle at the time of the ﬁrst blood drawing.them to serum p,p´-DDE levels in lipid bases
(nanograms per gram) as follows: the arith-
metic mean serum levels of p,p´-DDE in wet
bases (nanograms per milliliter) were multi-
plied by a factor of 129.8 to convert them to
the arithmetic mean of serum levels in lipid
basis (nanograms per gram), and otherwise
the arithmetic means of adipose tissue levels
of p,p´-DDE were divided by a factor of 4.2
to estimate the corresponding serum levels in
lipid basis (nanograms per gram) (López-
Carrillo et al. 1999).
The percent of recovery of p,p´-DDE lev-
els was not considered. Five articles did not
provide mean values of p,p´-DDE and thus
were not included (Dorgan et al 1999; Hoyer
et al 1998, 2000b; Laden et al. 2001b;
Stellman et al. 2000); also not included were
two others that reported adjusted mean values
of p,p´-DDE (Zheng et al. 1999, 2000) and
three in which the p,p´-DDE levels were sta-
tistically modeled through the contents of
triglycerides, serum, and total cholesterol
(Dello Iacovo et al. 1999; Hunter et al. 1997;
Moysich et al. 1998). Therefore, we included
12 studies in this step of the analysis. We esti-
mated the trend of the mean p,p´-DDE body
burden levels in nanograms per gram accord-
ing to the year when the biologic samples
were collected by linear regression.
To evaluate the gradient of p,p´-DDE
body burden captured by studies of interest,
we plotted the middle point of p,p´-DDE
levels in nanograms per gram in serum
(according to the methodology already
described) for each category of exposure,
against the corresponding ORs reported by
17 studies. We did not include two studies
because no information on the magnitude of
p,p´-DDE quartile distribution was provided
(Hoyer et al. 1998, 2000b) and three studies
in which p,p´-DDE was lipid-adjusted by
regression methods (Dello Iacovo et al. 1999;
Hunter et al. 1997; Moysich et al. 1998). All
the statistical analyses were performed using
the software Stata release 7.0 (Stata Corp.,
College Station, TX, USA). 
Results
Tables 1, 2 and 3 describe the 22 studies that
were included in the meta-analysis. All were
case–control studies, and of these nine were
prospective (nested case–control) (Dorgan et
al. 1999; Helzlsouer et al. 1999; Hoyer et al.
1998, 2000b; Hunter et al. 1997; Krieger et al.
1994; Laden et al. 2001b; Wolff et al. 1993,
2000b) and 13 retrospective (Aronson et al.
2000; Dello Iacovo et al. 1999; Demers et al.
2000; López-Carrillo et al. 1997; Mendonca
et al. 1999; Millikan et al. 2000; Moysich et al.
1998; Romieu et al. 2000; Stellman et al.
2000; van´t Veer et al. 1997; Wolff et al.
2000a; Zheng et al. 1999, 2000). Among the
retrospective studies, four were population-
based case–control studies (Dello Iacovo et al.
1999; Millikan et al. 2000; Moysich et al.
1998; van´t Veer et al. 1997) and seven were
clinic-based case–control studies (Aronson
et al. 2000; López-Carrillo et al. 1997,
Mendonca et al. 1999; Stellman et al. 2000;
Wolff et al. 2000a; Zheng et al. 1999, 2000);
in one study only a subsample of a population-
based case–control study population was ana-
lyzed (Romieu et al. 2000); and another study
included two types of controls: population and
clinical (Demers et al. 2000). All the studies are
presented in the tables according to decreasing
date of publication and design features.
Thirteen studies were conducted in the
United States (Dorgan et al. 1999; Helzlsouer
et al. 1999; Hunter et al. 1997; Krieger et al.
1994; Laden et al. 2001b; Millikan et al.
2000; Moysich et al. 1998; Stellman et al.
2000; Wolff et al. 1993, 2000a, 2000b;
Zheng et al. 1999, 2000), two in Canada
(Aronson et al. 2000; Demers et al. 2000),
two in Denmark (Hoyer et al. 1998, 2000b),
two in Mexico (López-Carrillo et al. 1997;
Romieu et al. 2000), one in Italy (Dello
Iacovo et al. 1999), one in Germany,
Netherlands, Ireland, Switzerland, Spain
(van´t Veer et al. 1997), and one more in
Brazil (Mendonca et al. 1999). The number
of cases ranged from 58 in the study per-
formed by Wolff et al. (1993) to 456 in the
study performed by Millikan et al. (2000).
The inclusion criteria of the referent
groups varied among studies. Individuals with
skin cancer were accepted in the control
group by some studies, (Dorgan et al. 1999;
Helzlsouer et al. 1999; Wolff et al. 2000a)
whereas in others controls had been diag-
nosed with benign breast disease (Aronson et
al. 2000; Stellman et al. 2000; Wolff et al.
2000a), and in the remaining studies only
healthy individuals and/or subjects with no
cancer diagnosis made up the comparison
group (Dello Iacovo et al. 1999; Demers et al.
2000; Hoyer et al. 1998, 2000b; Hunter et al.
1997; Krieger et al. 1994; Laden et al. 2001b;
López-Carrillo et al. 1997; Mendonca et al.
1999; Millikan et al. 2000; Moysich et al.
1998; Romieu et al. 2000; van´t Veer et al.
1997; Wolff et al. 1993, 2000b).
In most studies, body burden levels of
p,p´-DDE were measured in serum samples
(Dello Iacovo et al. 1999; Demers et al. 2000;
Dorgan et al. 1999; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000b; Hunter et al. 1997;
Krieger et al. 1994; Laden et al. 2001b; López-
Carrillo et al. 1997; Mendonca et al. 1999;
Millikan et al. 2000; Moysich et al. 1998;
Romieu et al. 2000; Wolff et al. 1993, 2000a,
2000b; Zheng et al. 2000), but in four studies,
adipose tissue from the breast (Aronson et al.
2000; Stellman et al. 2000; Zheng et al. 1999)
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Table 2. Retrospective epidemiologic population-based case–control studies on p,p´-DDE and breast cancer risk.
Controlled variablesa
Cases/controls Reproductive History of Other p,p´-DDE
Reference, location (n) Controls Biologic specimen Age variables breast cancer variables ORs (95% CI)
Millikan et al. 2000 456/389 Free of disease Serum X X X Xb High vs. low tertile
North Carolina, USA 1.09 (0.79–1.51)
Demers et al. 2000 315/307 Free of disease Serum X X X Xc High vs. low quintile
Québec, Canada 1.00 (0.60–1.67)
Romieu et al. 2000 120/126 Free of disease Serum X X X Xd High vs. low quartile
Mexico City, Mexico (subsample) 3.81 (1.14–12.80)
p for trend = 0.02
Dello Iacovo et al. 1999 170/190 Free of disease Serum X X — Xe High vs. low tertile
Naples, Italy 1.24 (0.70–2.20)
Moysich et al. 1998 154/192 Free of disease Serum X X X Xf High vs. low tertile
Western New York State, USA 1.34 (0.71–2.55)
van´t Veer et al. 1997 265/341 Free of disease Buttocks X X — Xg,h High vs. low quartile
Germany, Netherlands, Adipose tissue Except breast- 0.48 (0.25–0.95)
Northern Ireland, feeding p for trend = 0.02
Switzerland, Spain
BMI, body mass index.
aIn design or analysis. bHormone replacement treatment, income and race, BMI, age. cRegion of residence and history of benign breast disease, BMI. dDDT serum levels, BMI, socioe-
conomic status. eBMI, cholesterol. fFruit and vegetable intake, lipid serum, education, and BMI. gHospital controls and population controls were used together. hAlcohol consumption,
study site, and BMI.or the buttocks (van´t Veer et al. 1997) were
the biologic matrices chosen to estimate the
cumulative exposure to p,p´-DDE. The collec-
tion of biologic specimens dated back to about
10–25 years before the diagnosis of breast can-
cer in the prospective case–control studies
(Dorgan et al. 1999; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000b; Hunter et al. 1997;
Krieger et al. 1994; Laden et al. 2001b; Wolff
1993, 2000b) to the period immediately
around the date of diagnosis in all retrospective
studies (Aronson et al. 2000; Dello Iacovo et al.
1999; Demers et al. 2000; López-Carrillo et al.
1997, Mendonca et al. 1999; Millikan et al.
2000; Moysich et al. 1998; Romieu et al. 2000;
Stellman et al. 2000; van´t Veer et al. 1997;
Wolff et al. 2000a; Zheng et al. 1999, 2000).
The results of all studies were controlled by
the age of the participants. The control of
other potential confounders, either in the
design or the analysis, was distinct across the
studies. History of breast-feeding was not con-
sidered in six studies (Dorgan et al. 1999;
Hoyer et al. 1998, 2000b; Krieger et al. 1994;
Stellman et al. 2000; van´t Veer et al. 1997),
and parity and menopausal status were con-
trolled in most studies but not in two (Dorgan
et al. 1999; Stellman et al. 2000). History of
familial breast cancer and/or benign breast dis-
ease was controlled in most of the studies
(Aronson et al. 2000; Demers et al. 2000;
Helzlsouer 1999; Hunter 1997; Laden et al.
2001b; López Carrillo et al. 1997; Mendonca
et al. 1999; Millikan et al. 2000; Moysich et al.
1998; Wolff et al. 1993, 2000a, 2000b; Zheng
et al. 2000) as well as body mass index
(Aronson et al. 2000; Dello Iacovo et al. 1999;
Demers et al. 2000; Helzlsouer et al. 1999;
Hunter et al. 1997; Krieger et al. 1994; Laden
et al. 2001b; López-Carrillo et al. 1997;
Millikan et al. 2000; Moysich et al. 1998;
Romieu et al. 2000; Stellman et al. 2000; van´t
Veer et al. 1997; Wolff et al. 2000b; Zheng
et al. 1999, 2000). Other adjustment variables
were fasting status (Hunter et al. 1997; Laden
et al. 2001b), day of menstrual cycle at the date
of blood sampling (Helzlsouer et al. 1999;
Wolff et al. 1993, 2000b), vital and/or income
status (Hoyer et al. 1998, 2000b; Millikan
et al. 2000; Zheng et al. 1999, 2000), physical
activity (Hoyer et al. 1998), use of hormonal
replacement therapy (Aronson et al. 2000;
Laden et al. 2001b; Millikan et al. 2000;
Hunter et al. 1997; Zheng et al. 2000),
tobacco smoking (Aronson et al. 2000; Hoyer
et al. 1998; Mendonca et al. 1999), and alco-
hol consumption (Aronson 2000; Hoyer et al.
1998; van´t Veer et al. 1997) as well as intake
of fruits, vegetables (Moysich et al. 1998), and
fat (Aronson et al. 2000; Zheng et al. 2000).
Overall, the data provided by the pub-
lished studies do not support an association
between p,p´-DDE body burden levels and
breast cancer risk, because the summary OR
was 0.97 (95% CI, 0.87–1.09) (Figure 1). We
found no evidence for signiﬁcant overall het-
erogeneity in the OR [χ2 = 27.93; degrees of
freedom (df) = 23; p = 0.218].
Summary ORs for prospective and retro-
spective population-based case–control and
retrospective hospital-based case–control stud-
ies were 0.91 (95% CI, 0.74–1.12), 1.11
(95% CI, 0.89–1.38), and 0.93 (95% CI,
0.77–1.12), respectively (Figure 2). Although
summary ORs did not show signiﬁcant hetero-
geneity within prospective or retrospective hos-
pital-based case–control studies (χ2 = 10.68;
df = 9; p = 0.298, and χ2 = 4.107; df = 7;
p = 0.767, respectively), we found a borderline
statistically significant test of heterogeneity
within retrospective population-based
case–control studies (χ2 = 11.23; df = 5;
p = 0.047) in the study performed by van’t
Veer et al. (1997).
Summary ORs were not different for the
16 studies where breast-feeding was con-
trolled as confounder (Aronson et al. 2000;
Dello Iacovo et al. 1999; Demers et al. 2000;
Helzlsouer et al. 1999; Hunter et al. 1997;
Laden et al. 2001b; López-Carrillo et al. 1997;
Mendonca et al. 1999; Millikan et al. 2000;
Moysich et al. 1998; Romieu et al. 2000;
Wolff et al. 1993, 2000a, 2000b; Zheng et al.
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Table 3. Retrospective epidemiologic (hospital-based case–control) studies on p,p´-DDE and breast cancer risk.
Controlled variablesa
Cases/controls Reproductive History of Other p,p´-DDE
Reference, location (n) Controls Biologic specimen Age variables breast cancer variables ORs (95% CI)
Stellman et al. 2000 232/323 Benign breast Breast adipose X — — Xb High vs. low tertile
New York State, USA disease and surgical- tissue 0.74 (0.44–1.25)
nonbreast diseases
Demers et al. 2000 315/219 Free of gynecologic Serum X X X Xc High vs. low quintile
Québec, Canada diseases 1.36 (0.71–2.63)
Aronson et al. 2000 217/213 Benign breast Breast adipose X X X Xd High vs. low quartile
Ontario, Canada disease tissue 1.62 (0.84–3.11)
Wolff et al. 2000a 175/181/175 Benign breast Serum X X X Xe High vs. low tertile
New York City, USA disease except BBD 0.93 (0.56–1.5)
with hyperplasia or
atypia and non-
benign disease and
free of cancer except
skin cancer
Zheng et al. 1999 304/186 Benign breast Breast adipose X X — Xf High vs. low quartile
Connecticut, USA disease except tissue 0.9 (0.5–1.5)
atypical hyperplasia
and normal breast
tissue
Zheng et al. 2000 326/347 Benign breast Serum X X X Xg High vs. low quartile
Connecticut, USA disease except 0.96 (0.67–1.36)
atypical hyperplasia
and normal breast
tissue
Mendonca et al. 1999 177/350 Free of disease Serum X X X Xh High vs low quintile
Rio de Janeiro, Brazil (hospital visitor) 0.83 (0.4–1.6)
López-Carrillo et al. 1997 139/139 Free of cancer or any Serum X X X Xi High vs. low tertile
Mexico City, Mexico other breast disease (0.41–1.42)
BMI, body mass index.
aIn design or analysis. bHospital, BMI, race. cRegion of residence and history of benign breast disease, BMI. dStudy site, present use of hormonal replacement therapy, BMI, fat intake,
race, alcohol intake, smoking. eRace, BMI, age. fIncome 10 years before the disease diagnosis or interview, BMI, race. gBMI, lifetime months of hormone replacement therapy, dietary
fat intake, race, and study site. hTobacco smoking and breast size, educational level. iBMI.1999, 2000) and the estimate was 1.01
(95% CI, 0.88–1.16), compared to the OR for
studies in which breast-feeding was uncon-
trolled (OR = 0.87; 95% CI, 0.68–1.10)
(Dorgan et al. 1999; Hoyer et al. 1998, 2000b;
Krieger et al. 1994; Stellman et al. 2000; van´t
Veer et al. 1997). There were no differences
either for the 18 studies using blood serum as
biologic specimen 1.00 (95% CI, 0.88–1.14)
(Dello Iacovo et al. 1999; Demers et al. 2000;
Dorgan et al. 1999; Helzlsouer et al. 1999;
Hoyer et al. 1998, 2000b; Hunter et al. 1997;
Krieger et al. 1994; Laden et al. 2001b; López-
Carrillo et al. 1997; Mendonca et al. 1999;
Millikan et al. 2000; Moysich et al. 1998;
Romieu et al. 2000; Wolff et al. 1993, 2000a,
2000b; Zheng et al. 2000) or for studies that
used adipose tissue 0.84 (95% CI, 0.62–1.13)
(Aronson et al. 2000; Stellman et al. 2000;
Zheng et al. 1999; van´t Veer et al. 1997)
(Table 4). No evidence of publication bias was
found (p = 0.253).
In Figure 3 we depict a significantly
decreasing trend (β = –130.59; p = 0.001) of
the mean levels of p,p´-DDE that were evalu-
ated by the studies analyzed, according to the
date when the biologic sample was collected.
All those levels were converted to the corre-
sponding equivalent nanograms per gram in
lipid serum bases. Significantly, p,p´-DDE
levels as reported by the study carried out in
Mexico City by Romieu et al. (2000), were at
great variation with the other studies per-
formed at about the same time, including the
one performed in that same city (López-
Carrillo et al. 1997).
In Figure 4 we present the ORs for the
effect of p,p´-DDE on breast cancer risk from
each study, according to the gradient of the
p,p´-DDE body burden levels expressed as
nanograms per gram in serum lipid bases
(middle point of p,p´-DDE levels for each cat-
egory of exposure). The range of that gradient
varied from 84.37 ng/g in the study per-
formed by Mendonca et al. (1999), to
12928.08 ng/g in the study by Krieger et al.
(1994). As shown in Figure 4, most studies
reported p,p´-DDE body burden levels in the
range of 84.37–9,000 ng/g and yielded nega-
tive results, with two exceptions (Romieu et al.
2000; Wolff et al. 1993). The studies that had
the highest levels of p,p´-DDE body burden
levels (9,001–12928.08 ng/g) did not show an
increasing risk of breast cancer due to
p,p´-DDE body burden levels (Dorgan et al.
1999; Krieger et al. 1994; van´t Veer et al.
1997).
Discussion
The results of the meta-analysis of 22 studies
showed no evidence for an association between
p,p´-DDE body burden levels and breast can-
cer risk. The summary OR reported in this
manuscript was 0.97 (95% CI, 0.87–1.09),
very similar to the one recently estimated from
a pooled analysis of ﬁve studies (OR = 0.99;
95% CI 0.77–1.27) performed in the United
States (Laden et al. 2001a) and had the same
covariates to be included in the logistic models.
Some studies (Hunter 1997, Laden 2001a,
Wolff 1993, 2000b) apparently made repeated
use of some subjects as part of their study pop-
ulations in subsequent papers. Hence, one
additional check was to remove in subsequent
steps those studies for which we believed that
such condition could be met, and the estimates
of summary ORs remained almost unaltered
(data not shown).
An intrinsic ﬂaw in many environmental
epidemiologic studies is the lack of an adequate
gradient of exposure both within and through-
out the different populations studied. On aver-
age, the difference between the highest and the
lowest levels of p,p´-DDE in the 22 studies was
6928.92 ± 6414.5 ng/g. The studies that had
the widest internal gradient of exposure were
negative (Dorgan et al. 1999; Krieger et al.
1994) as were the studies that reported the
highest levels of p,p´-DDE. (Dorgan et al.
1999; Krieger et al. 1994). In this regard, evi-
dence from occupational studies, which evalu-
ated much higher levels of p,p´-DDE exposure,
does not suggest a high risk for breast cancer
(Austin et al. 1989; Fleming et al. 1999).
Hence, we believe we can rule out the possibil-
ity that contradictory results among the 22
studies are caused by differences in p,p´-DDE
levels.
Methodologic features among the studies
that may explain the contradictory results
include differences in the temporal relation-
ship between the measurement of p,p´-DDE
Article | A meta-analysis of DDT and breast cancer risk
Environmental Health Perspectives • VOLUME 112 | NUMBER 2 | February 2004 211
Figure 1. Accumulated meta-analysis; summary OR = 0.97 (95% CI, 0.87–1.09).
aBiologic samples taken in 1974. bBiologic samples taken in 1989. cControls are population based. dControls are clinical based.
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Figure 2. Meta-analysis according to type of design: (A) prospective studies (nested case–control); (B) retrospective studies (population-based case–control);
(C) retrospective studies (hospital-based case–control). 
aBiologic samples taken in 1974. bBiologic samples taken in 1989. cControls are population based. dControls are clinical based.
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A B Clevels and the diagnosis of breast cancer. Levels
of p,p´-DDE that are measured around the
date of diagnosis may not reﬂect the real expo-
sure at disease onset. However in this article
we showed that the association between
p,p´-DDE and breast cancer risk did not vary
according to the type of the study (i.e.,
prospective case–control studies vs. retrospec-
tive case–control studies), and this informa-
tion should be interpreted as evidence that
temporality does not explain different results
among the studies.
Confounding is a potential explanation
for inconsistent epidemiologic results. Among
the confounders that might distort the rela-
tionship between p,p´-DDE and breast cancer
risk are breast-feeding and diet. Lactation is a
way of eliminating the body burden levels of
p,p´-DDE (López-Carrillo et al. 2001) and
has been found to decrease the risk of breast
cancer in several studies (Romieu et al. 1996).
However, we found no heterogeneity in our
meta-analysis to assign explanatory relevance
to the lack of control by this variable in some
of the published studies. Yet this analysis is
not enough to rule out the possibility that
equivocal results might be partially explained
by differences in the ranges of values for the
adjustment variables across the studies; more-
over, measurement error in the confounding
variables is likely to result in unpredictably
biased estimates of effect for the main variable
of interest when adjustments are performed.
Residues of p,p´-DDE were reportedly
found in several foods (fish, dairy products,
meat) (Galván-Portillo et al. 2002), and the
consumption of some of them may be related
to breast cancer risk. For example, meat intake
is related to an excess risk for breast cancer,
whereas ﬁsh intake, presumably because of the
presence of omega-3 fatty acids, seems to be
inversely related to breast cancer incidence
(World Cancer Research Fund 1997). A study
performed by Verma et al. (1997) showed that
genistein, an isoﬂavonoid present in soybeans,
and curcumin, a component of turmeric pow-
der and also a widely used spice, can inhibit the
action of pesticides with estrogenic activity. The
great variation in breast cancer risk raises the
possibility that dietary factors are related to its
etiology. In this regard, dietary factors and par-
ticularly specific compounds such as phyto-
estrogen were scarcely or not at all taken into
account as covariates in studies of p,p´-DDE
and breast cancer risk; thus, the lack of adjust-
ment by these variables might partially explain
the equivocal results so far available.
Another methodologic issue of concern is
the type of controls that were enrolled—i.e.,
hospital or population based—in that one
should expect that p,p´-DDE body burden lev-
els were not related to the diseases identiﬁed
among clinical controls, and also that popula-
tion controls actually constitute a representative
sample of the p,p´-DDE body burden levels
present in the target population (Rothman and
Greenland 1998). We were not able to find
heterogeneity according to the study design,
except for a borderline signiﬁcant result within
retrospective population-based case–control
studies (χ2 = 11.23; df = 5; p = 0.047). And this
variation mainly arose from the study by van’t
Veer et al. (1997), which assembled a referent
group that combined hospital- and population-
based controls and provided no explanation for
such an unusual combination. 
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Table 4. Overall ORs for breast cancer risk and p,p´-DDE body burden levels.
Studies included in the analysis No of studiesa OR (95% CI)
All 22 0.97 (0.87–1.09)
Prospective nested case–control 9 0.91 (0.74–1.12)
Retrospective case–control
Population based 6 1.11 (0.89–1.38)
Hospital based 7 0.93 (0.77–1.12)
Breast-feeding control
Yes 16 1.01 (0.88–1.16)
No 6 0.87 (0.68–1.10)
p,p´-DDE levels
Serum 18 1.00 (0.88–1.14)
Adipose tissue 4 0.84 (0.62–1.13)
aIn total, 22 studies were useful for the purposes of this table; Demers et al. (2000) contributed data for clinical and popu-
lation controls, which were considered separately. That was also the case for Helzlsouer et al. (1999), in which serum
samples were reported for two different moments in time: 1974 and 1989. Thus the sample size for the analysis became 24.
Figure 3. Mean levels of p,p´-DDE (ng/g) in 12 reported studies according to the date of sample collection.
∆, ﬁtted values.
aBiologic samples taken in 1974. bBiologic samples taken in 1989.
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Figure 4. Effect of p,p´-DDE on breast cancer risk from each study according to p,p´-DDE (ng/g) body burden
levels. ln, natural logarithm.
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0Consistent with the prohibition against
DDT, which took place between 1972 and
1997 in many countries, a decreasing trend in
p,p´-DDE levels is observed when considering
the year of biologic sample collection, with
one exception (Romieu et al. 2000), a study
that reported p,p´-DDE levels about 5-fold
higher than the ones previously observed in
the same area and a similar study population
(López-Carrillo et al. 1997).
The two Mexican studies were performed
among residents of Mexico City, where DDT
has never been used, although this substance
was still in use until 1997 for vector control
in the tropical areas of the country. One may
speculate that the route of exposure to
p,p´-DDE for residents of Mexico City was
the ingestion of contaminated foods brought
from areas where DDT was being sprayed
(Torres-Arreola et al. 1999). Nevertheless,
body-burden levels should not be appreciably
different between the two studies or from
those observed in other urban areas of the
world [levels of exposure reported by López-
Carrillo et al. (1997)]. To strengthen this
point, a reproducibility study was performed
between a U.S. laboratory and the laboratory
that processed the samples of the first
Mexican study (see also Torres-Arreola 2002).
The results showed a very high correlation
coefficient (0.985), and the mean values of
p,p´-DDE for 10 spiked serum samples were
21.47 ± 7.09 and 19.24 ± 7.20, respectively
(Torres-Arreola et al. 2002). Regrettably, no
similar information is available for the study
by Romieu et al. (2000) to exclude a system-
atic error that could explain the unexpectedly
high levels of p,p´-DDE they reported.
In the context of the measurement of
exposure, we found no evidence that the type
of biologic specimen used to measure
p,p´-DDE levels was related to the conﬂicting
results stemming from the published studies.
Moreover, in a previous study our research
group demonstrated that the relationship
between p,p´-DDE levels in serum and adi-
pose tissue is close to unity when the results
are normalized and adjusted by lipid content
(López-Carrillo et al. 1999), and that ﬁnding
is consistent with the lack of heterogeneity
herein reported.
The lack of a positive association between
p,p´-DDE body burden levels and breast can-
cer risk could be explained by the low estro-
genicity of p,p´-DDE, compared with the less
persistent metabolites of technical DDT,
which are p,p´-DDT and o,p´-DDT. In vivo
tests showed no increase in wet uterine weight
gain in immature or ovaryectomized rodents
and a weak binding of estradiol to rodent
uterine receptors or to any form of human
estrogen receptors in relation to p,p´-DDE.
Since the 1970s, the major route of exposure
to DDT has been the far less estrogenic
p,p´-DDE contained in the diet, and not the
more estrogenic o,p´-DDT found in technical
DDT, which was sprayed as an insecticide
(Snedeker 2001). In this context, the signiﬁ-
cant association with breast cancer at rela-
tively low levels of exposure to p,p´-DDE
reported by Wolff et al. in 1993 might be a
chance ﬁnding (i.e. a type I error).
Some aspects are not yet accounted for in
the studies performed so far. The exposure to
DDT during the critical periods of develop-
ment—from conception through adoles-
cence—may be related to adult breast cancer;
however, individual variations in metabolizing
enzymes of DDT and its derivatives are likely
to modify the consequences of the exposure to
this compound, and certainly that is an incipi-
ent area for health research. Nevertheless, we
believe that the results of this meta-analysis
should be regarded as strong evidence against
the putative association between DDT and
breast cancer risk.
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